Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.

Targeted oncology - 1 Feb 2020

Olbryt Magdalena, Pigłowski Wojciech, Rajczykowski Marcin, Pfeifer Aleksandra, Student Sebastian, Fiszer-Kierzkowska Anna

Abstract excerpt

BACKGROUND: Molecularly targeted therapy has revolutionized the treatment of advanced melanoma. However, despite its high efficiency, a majority of patients experience relapse within 1 year of treatment because of acquired resistance, and approximately 10-25% patients gain no benefit from these agents owing to intrinsic resistance. This is mainly caused by the genetic heterogeneity of melanoma cells. OBJECTIVE:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous Melanoma Detection and Management
Share to Genetic Profile

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma Diagnosis and Treatment

Share to High-Throughput Nucleotide Sequencing

Share to Melanoma

Share to Melanoma and MAPK Pathways

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 31980996
DOI: 10.1007/s11523-020-00695-0
PMCID: PMC7028806

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.PMID 31980996Read ↗

A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping.Semantic proximity Read ↗

The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response.Semantic proximity Read ↗

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma PatientsSemantic proximity Read ↗

A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.Semantic proximity Read ↗

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.Semantic proximity Read ↗

Somatic mutation analysis in melanoma using targeted next generation sequencing.Semantic proximity Read ↗

Impact of molecular testing in advanced melanoma on outcomes in a tertiary cancer center and as reported in a publicly available database.Semantic proximity Read ↗

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.Semantic proximity Read ↗

Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.Semantic proximity Read ↗

Validation of an NGS mutation detection panel for melanomaSemantic proximity Read ↗

A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants.Semantic proximity Read ↗

Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.